Juhi Juneja, Bristol-Myers Squibb to Speak at Protein-Protein Interaction, Oct. 23-24, 2014 in Boston
Juhi Juneja, Senior Research Investigator at Bristol-Myers Squibb to Speak at 2nd Protein-Protein Interaction Conference, October 23-24, 2014 in Boston, MA.
Boston, MA, July 22, 2014 --(PR.com)-- Juhi Juneja, Senior Research Investigator at Bristol-Myers Squibb, will give a presentation on, “Albumin-Binding Adnectin: Pharmacokinetic Enhancement Solution” at the 2nd Protein-Protein Interaction Conference to be held on October 23-24, 2014 in Boston, MA by GTCbio.
GTCbio's upcoming 2nd Protein-Protein Interaction Conference to be held on October 23-24, 2014 in Boston, MA will have sessions that cover novel techniques, new algorithms and databases for PPIs, and potential druggable sites for disrupting protein-protein interactions. Attendees will gain an enhanced understanding of the molecular basis of peptide and protein aggregation and insights into the design of inhibitors of peptide and protein aggregation. Some focused topics they will discuss is how inhibiting PPIs can be a promising therapeutic target, PPI interactions within the TNF family, the first small-molecule inhibitors for the CD40–CD40L, and much more including the fundamental aspects of protein-protein interactions. For more information, please visit: www.gtcbio.com/conferences/ppi-overview
This conference is part of the larger Protein Discovery Summit 2014, which consists of the following co-located conferences:
3rd Protein Kinases & Drug Design
2nd Protein Expression, Characterization & Purification
2nd Antibody & Protein Therapeutics
2nd Protein-Protein Interaction
GTCbio's upcoming 2nd Protein-Protein Interaction Conference to be held on October 23-24, 2014 in Boston, MA will have sessions that cover novel techniques, new algorithms and databases for PPIs, and potential druggable sites for disrupting protein-protein interactions. Attendees will gain an enhanced understanding of the molecular basis of peptide and protein aggregation and insights into the design of inhibitors of peptide and protein aggregation. Some focused topics they will discuss is how inhibiting PPIs can be a promising therapeutic target, PPI interactions within the TNF family, the first small-molecule inhibitors for the CD40–CD40L, and much more including the fundamental aspects of protein-protein interactions. For more information, please visit: www.gtcbio.com/conferences/ppi-overview
This conference is part of the larger Protein Discovery Summit 2014, which consists of the following co-located conferences:
3rd Protein Kinases & Drug Design
2nd Protein Expression, Characterization & Purification
2nd Antibody & Protein Therapeutics
2nd Protein-Protein Interaction
Contact
GTCbio
Kristen Starkey
626-256-6405
http://www.gtcbio.com
635 W. Foothill Blvd.
Monrovia, CA 91016
fax: 626-466-4433
Contact
Kristen Starkey
626-256-6405
http://www.gtcbio.com
635 W. Foothill Blvd.
Monrovia, CA 91016
fax: 626-466-4433
Categories